Gene Therapy Clinical Trial Webpage
What is gene therapy?
Gene therapy can be defined as the introduction of genetic material to cells of individuals for therapeutic benefit. In simple terms, it involves providing a healthy functional copy of a gene to the patient’s cells to compensate for a defective copy that causes the disease. Ideally this treatment would only need to be administered once in the lifetime of the patient. Even though the concept
underlying gene therapy is straightforward, delivering genes into cells of a living organism is a very challenging process. Therefore, an essential component of gene therapy studies is the development of vectors that can efficiently deliver genetic material into cells.
For Type 1 Gaucher disease, there are a number of gene therapy clinical trials currently looking for participants to take part in. We have compiled information about these trials below with the aim of making it easy for the community to understand the similarities and differences between them.
There are multiple factors to consider when deciding whether or not to take part in any form of medical research. Please note that each clinical trial is unique and the intention of capturing the information below is not to suggest that any trial is preferable to another.
If you or a loved one are interested in taking part in a clinical trial, please speak to your doctor about the options available to you.
Overview of clinical trials using gene therapy for the treatment of Type 1 Gaucher disease
|
|
|
|
|
|
||
|
|
||||||
|
Study name |
PROCEED |
GALILEO-1 |
Guard1 |
Usually, trials have specific names to make them easier |
||
|
ID number |
The ID code connects to a clinicaltrial.gov page capturing all |
|||||
|
Status |
Recruiting |
Recruiting |
Stopped (due to |
|
||
|
Study phase |
1/2 |
1/2 |
1/2 |
The phase explains how far an experimental medicine is in its |
||
|
Aim of the study |
As all three studies are |
|
||||
|
Gene Therapy |
LY3884961 |
FLT201 |
AVR-RD-02 |
Each company will have given their experimental medicine a name |
||
|
Other medicines given during the study? |
Methylprednisolone Sirolimus Prednisone |
Unknown
Any |
Busulfan
It is possible |
It is not unusual for other medicines to be given |
||
|
Study locations (see map below) |
US-based study, looking to enroll approx. 15 |
Global study, looking to enroll approx. 18 |
US and Canada-based study, which has enrolled 7 |
|
||
|
Length of study (incl. screening) |
For those taking part, |
For those taking part, |
For those taking part, |
|
||
|
Number of visits |
4 visits in the first two months, then one visit then once per year for 3 years |
Unknown
The number of visits will be confirmed with your treatment team. All people who have received the |
Approximately 30 visits over the course of the |
|
||
|
Costs of participation covered? |
Any travel
|
|
||||
|
Key criteria to take part (inclusion criteria) |
18 – 65 years old Have the bi-allelic GBA1 mutation <![if !supportLists]>» <![if !supportLists]>» <![if !supportLists]>» <![if !supportLists]>» |
18+ years old Have the GBA1 mutation <![if !supportLists]>» <![if !supportLists]>»
|
18 – 50 years old (post puberty) Have the GBA1 mutation <![if !supportLists]>» <![if !supportLists]>» <![if !supportLists]>»
Open to both people with at least 2 years of stable ERT treatment |
|
||
|
Key exclusion criteria |
<![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x |
<![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x |
<![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x <![if !supportLists]>x |
|
||
|
|
Each study will have additional inclusion and |
|
||||
|
What does the study look like? |
This study is set up so both the |
You may come across the terms ‘non-randomised’ |
||||
|
Three study groups will be set up to investigate |
A single participant group will be set up for this |
Two study groups will be included, one for those |
||||
|
Delivery of treatment |
Each participant will be given a single |
Each participant will be given a single |
Each participant will be given a single
|
|
||
|
Pre-screening & conditioning? |
<![if !supportLists]>· <![if !supportLists]>·
|
<![if !supportLists]>· <![if !supportLists]>·
|
<![if !supportLists]>· <![if !supportLists]>· <![if !supportLists]>· <![if !supportLists]>· Conditioning |
|
||
Clinical trial sites
BLUE: Prevail Therapeutics | RED: Freeline Therapeutics | GREEN: AVROBIO
Further details of the
locations/hospitals can be found in by clicking the links above.


































